I dedicate this thesis to my Father

Ly Luan Le

You dedicated your life to your family and community
You succeeded despite hardship and taught me to succeed despite hardship
You had the potential and the dream to pursue your PhD,
but never the opportunity
I share your love of knowledge and have fulfilled your dream now.
Statement

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Phuong-Phi Le and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Phuong-Phi Le
Date:

Signature:
# Table of Contents

Statement .................................................................................................................................................. 5  
Table of Contents ..................................................................................................................................... vii  
List of Tables ........................................................................................................................................... xv  
List of Figures ........................................................................................................................................... xvi  
Glossary .................................................................................................................................................... xvii  
Abstract ................................................................................................................................................... xix  
Acknowledgements ................................................................................................................................... xxi  
Chapter 1 Introduction ............................................................................................................................ 24  
    1.1 The research problem ....................................................................................................................... 24  
    1.2 Thesis aim and research questions .................................................................................................... 26  
        1.2.1 Thesis aim ................................................................................................................................... 26  
        1.2.2 My research questions ............................................................................................................. 26  
    1.3 Terminology ..................................................................................................................................... 27  
    1.4 Thesis structure ............................................................................................................................... 27  
Chapter 2 The background and context for my research ....................................................................... 30  
    2.1 Australian health care system ........................................................................................................... 30  
        2.1.1 Pharmacists and the pharmacy workforce in Australia ............................................................... 31  
            2.1.1.1 Medicine schedules in Australia ....................................................................................... 33  
    2.2 Opioid pharmacotherapy treatments in Australia .......................................................................... 34  
        2.2.1 Overview of opioid pharmacotherapy treatments in Australia ............................................... 34  
        2.2.2 The opioid substitution treatment (OST) program in South Australia .................................. 36  
            2.2.2.1 OST patients in South Australia .................................................................................... 37  
            2.2.2.2 Medical prescribers for OST in South Australia .............................................................. 39  
            2.2.2.3 Pharmacy provision of OST in South Australia ............................................................... 40  
                2.2.2.3.1 Funding arrangements for pharmacy OST providers ........................................ 42  
    2.3 Chapter summary ............................................................................................................................. 43  
Chapter 3 Pharmacist prescribing practices and OST: a literature review ............................................ 44  
    3.1 Non-medical prescribing internationally .......................................................................................... 44  
        3.1.1 The evolution of prescribing ..................................................................................................... 44  
        3.1.2 International models of prescribing .......................................................................................... 46
3.1.3 Pharmacist prescribing abroad ................................................................. 48
3.1.4 Prescribing of controlled drugs ............................................................... 50
3.1.5 Training and education for international pharmacist prescribers ............. 51
3.2 Non-medical prescribing in Australia .......................................................... 54
  3.2.1 Australian non-medical prescribing practice ............................................. 54
  3.2.2 Non-medical prescribing by pharmacists in Australia ......................... 54
  3.2.2.1 Australian pharmacists ineligible to prescribe controlled drugs .......... 59
  3.2.3 Medical professional views on non-medical prescribing ......................... 61
3.3 Theories of pharmacy practice .................................................................. 62
  3.3.1 Prescription-focused approach ............................................................... 62
  3.3.2 Patient-centred care (PCC) .................................................................. 63
    3.3.2.1 Patient participation in decision making ........................................... 65
    3.3.2.2 Communication ............................................................................. 65
    3.3.2.3 Access to treatment ....................................................................... 66
    3.3.2.4 Continuous relationships ............................................................... 66
    3.3.2.5 Respect/privacy ............................................................................. 66
  3.3.3 Pharmacy privacy ................................................................................. 67
  3.3.4 Why PCC is important for OST patients ............................................... 70
3.4 The research gap ....................................................................................... 71
3.5 Chapter summary ..................................................................................... 72

Chapter 4 Methodology and methods .............................................................. 74
  4.1 Rationale for methodology ........................................................................ 74
  4.2 Methods for face-to-face interviews with patients ..................................... 75
  4.3 Recruiting and interviewing participants to the study ................................ 76
    4.3.1 Recruitment of participants ............................................................... 76
    4.3.2 Interview schedule and data collection .............................................. 77
    4.3.3 Participant demographics .................................................................. 80
    4.3.4 Participant motivations for participation ........................................... 82
    4.3.5 Data analysis: the framework approach ......................................... 82
  4.4 Evolution of the research question ............................................................ 83
  4.5 Methods for pharmacist focus group interviews ........................................ 84
  4.6 Recruiting and interviewing participants .................................................. 85
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6.1</td>
<td>Recruitment of participants for focus group interviews</td>
<td>85</td>
</tr>
<tr>
<td>4.6.2</td>
<td>Focus group interview schedule and data collection</td>
<td>88</td>
</tr>
<tr>
<td>4.6.3</td>
<td>Focus group participant demographics</td>
<td>89</td>
</tr>
<tr>
<td>4.6.4</td>
<td>Data analysis</td>
<td>91</td>
</tr>
<tr>
<td>4.7</td>
<td>Ethical approval and data storage</td>
<td>91</td>
</tr>
<tr>
<td>4.7.1</td>
<td>Data access approval</td>
<td>92</td>
</tr>
<tr>
<td>4.8</td>
<td>Study tour approach</td>
<td>92</td>
</tr>
<tr>
<td>4.8.1</td>
<td>Identifying and interviewing key informants</td>
<td>93</td>
</tr>
<tr>
<td>4.9</td>
<td>Reflexivity</td>
<td>94</td>
</tr>
<tr>
<td>4.9.1</td>
<td>My reflexivity</td>
<td>95</td>
</tr>
<tr>
<td>4.10</td>
<td>Chapter summary</td>
<td>101</td>
</tr>
</tbody>
</table>

## Chapter 5 Patients’ experiences with existing models of care | 102 |
| 5.1     | Introduction to three patient results chapters | 102  |
| 5.2     | Introduction to Chapter 5 | 103  |
| 5.3     | Variable access to and experiences of treatment | 105  |
| 5.3.1   | Variability of initial access to treatment | 105  |
| 5.3.2   | Difficulties in transferring from clinic to community setting | 110  |
| 5.3.3   | The implications of difficult access to treatment | 112  |
| 5.3.4   | Different expectations of access to and cost of treatment | 116  |
| 5.3.5   | Differing views on whether immediate treatment access is crucial | 116  |
| 5.3.6   | Differing pharmacy fees | 118  |
| 5.3.7   | Summary of theme: Variable access to and experiences of treatment | 119  |
| 5.4     | Variable monitoring of patients | 120  |
| 5.4.1   | Differences in pharmacist supervision and misuse of medication | 120  |
| 5.4.2   | Summary of theme: Variable monitoring of patients | 122  |
| 5.5     | Variable relationships with health professionals | 122  |
| 5.5.1   | Importance of patient relationship with the community pharmacist | 123  |
| 5.5.2   | Disjointed patient relationship with the clinic doctor | 124  |
| 5.5.3   | Variability in perceptions of privacy | 125  |
| 5.5.4   | Summary of theme: Variable relationships with health professionals | 125  |
| 5.6     | Chapter summary | 126  |
Chapter 6 Patient views on pharmacist co-prescribing for their opioid substitution treatment

6.1 Introduction .........................................................................................................................128

6.2 Patient-centred care .............................................................................................................128
  6.2.1 Enhanced choice .............................................................................................................129
  6.2.2 Increased patient empowerment and autonomy .............................................................130
  6.2.3 Suitability of co-prescribing for selected patients .........................................................131
  6.2.4 Power and manipulation ...............................................................................................132

6.3 Themes from patient views on pharmacist co-prescribing for OST ..................................135

6.4 Convenient access to services ............................................................................................138
  6.4.1 Convenient location .......................................................................................................138
  6.4.2 Reduced cost and number of visits to the doctor ..........................................................139

6.5 Improved monitoring of patients .........................................................................................140
  6.5.1 Improved monitoring of patients ....................................................................................140

6.6 Modification of roles and relationships with health professionals ..................................142
  6.6.1 Preferred medical practitioner roles .............................................................................143
  6.6.2 Impact of co-prescribing on pharmacists .....................................................................145
  6.6.3 Additional training for pharmacist co-prescribers .........................................................147
  6.6.4 Summary of theme: Modification of roles and relationships with health professionals .................................................................................................................................149

6.7 Chapter summary ................................................................................................................150

Chapter 7 Privacy in the pharmacy: the views of interviewed patients .................................152

7.1 Introduction ..........................................................................................................................152

7.2 Patients who had no privacy concerns ...............................................................................152

7.3 Views on privacy according to pharmacy layout .................................................................155
  7.3.1 Dosing at the front counter ...........................................................................................155
    7.3.1.1 Comfortable with front counter dosing ..................................................................155
    7.3.1.2 Not comfortable with front counter dosing ...........................................................156
  7.3.2 Dosing in a separate room .............................................................................................157
    7.3.2.1 Comfortable with dosing in a separate room ..........................................................158
    7.3.2.2 Not comfortable with dosing in a separate room ....................................................158
  7.3.3 Dosing in a screened or partitioned area inside the pharmacy .........................................161
7.4 Impact of relationship with pharmacist on patient experiences of privacy............162
7.5 Chapter summary ..........................................................................................164

Chapter 8 Pharmacist views on collaborative prescribing for opioid substitution treatment
....................................................................................................................................166

8.1 Introduction .......................................................................................................166
8.2 Focus group participant views on pharmacist prescribing .........................169
  8.2.1 Preference for independent or dependent prescribing ..............................169
  8.2.2 Working relationship with doctor within dependent prescribing model ....171
  8.2.3 Reasons for support of pharmacist prescribing ........................................172
  8.2.4 Summary of theme: Focus group participant views on pharmacist prescribing 178
8.3 Benefits of the co-prescriber model of care ....................................................179
  8.3.1 Benefits for patients .................................................................................179
    8.3.1.1 Improved convenience of treatment access .........................................179
    8.3.1.2 Improved monitoring of patients .........................................................182
    8.3.1.3 Increased vacancies for patients .........................................................184
    8.3.1.4 Increased ownership of own health ....................................................184
  8.3.2 Benefits for pharmacists ...........................................................................185
    8.3.2.1 Improved work satisfaction for pharmacists ..................................185
    8.3.2.2 Improved collaboration between doctors and pharmacists ..............186
  8.3.3 Benefits for doctors ...................................................................................187
    8.3.3.1 Improved collaboration between doctors and pharmacists ............187
    8.3.3.2 Reduced workload for doctors ..........................................................187
  8.3.4 Summary of theme: Benefits of the co-prescriber model of care ..........189
8.4 Barriers of the co-prescriber model of care ....................................................190
  8.4.1 Barriers for patients ..................................................................................190
    8.4.1.1 Manipulation of loopholes in the co-prescriber system ..................190
  8.4.2 Barriers for pharmacists .........................................................................193
    8.4.2.1 Pharmacist workload and work pressure concerns ......................193
    8.4.2.2 Unwanted responsibility of pharmacist co-prescribing .................194
    8.4.2.3 Pharmacy infrastructure .................................................................197
    8.4.2.4 Pharmacist competency .................................................................198
    8.4.2.5 Professional lack of interest in OST ...............................................199
8.4.3 Barriers for doctors ........................................................................................................200
  8.4.3.1 Professional encroachment .....................................................................................200
  8.4.3.2 Professional lack of interest in OST ....................................................................202
8.4.4 Summary of theme: Barriers of the co-prescriber model of care .......................203
8.5 Facilitators of the co-prescriber model of care ..........................................................203
  8.5.1 Facilitators for pharmacists .....................................................................................203
    8.5.1.1 Limited prescribing authority .........................................................................203
    8.5.1.2 Co-prescribing only for selected patients ......................................................205
    8.5.1.3 Collaborative management plan .....................................................................207
    8.5.1.4 Legislative and funding changes .....................................................................209
    8.5.1.5 Training for pharmacist co-prescribers .............................................................213
    8.5.1.6 Alternative and more efficient communication between doctors and
pharmacists ......................................................................................................................216
  8.5.2 Facilitators for doctors ............................................................................................216
    8.5.2.1 Alternative and more efficient communication between doctors and
pharmacists ......................................................................................................................216
8.5.3 Summary of theme: Facilitators of the co-prescriber model of care ...................220
8.6 Chapter summary ..........................................................................................................221
Chapter 9 Lessons learnt from a Canadian and US study tour of pharmacist prescribing.222
  9.1 Introduction ..................................................................................................................222
  9.2 Background ..................................................................................................................224
    9.2.1 Study tour aims ....................................................................................................224
    9.2.2 Selection of study tour locations ..........................................................................224
    9.2.3 Key insights ..........................................................................................................226
  9.3 Settings in which pharmacist prescribing was practised ..........................................228
    9.3.1 Pharmacist prescribers in hospital settings .......................................................228
      9.3.1.1 Prescribing controlled drugs ........................................................................229
    9.3.2 Pharmacist prescribers in community pharmacy settings ................................230
    9.3.3 Summary of settings in which pharmacist prescribing was practised .............231
  9.4 Facilitators of pharmacist prescribing .......................................................................231
    9.4.1 Facilitators in hospital and community settings ...................................................232
      9.4.1.1 Patient response and feedback about pharmacist prescribers ....................232
10.6 Chapter summary …………………………………………………………………………………261

Chapter 11 Conclusion and future directions……………………………………………………262

11.1 Summary of thesis chapters……………………………………………………………………263

11.2 Future directions…………………………………………………………………………………266

11.2.1 Australian pharmacy workforce……………………………………………………………266

11.2.2 Pharmacy layout ……………………………………………………………………………267

11.2.3 Shared electronic health records……………………………………………………………269

11.2.4 Funding models………………………………………………………………………………270

11.2.5 Future consultations with a wider range of stakeholders……………………………270

11.3 Concluding remarks …………………………………………………………………………271

Appendices ………………………………………………………………………………………272

Appendix 1. Poster advertisement to recruit patients……………………………………273

Appendix 2. Data analysis of patient interviews on the policy proposal …………………275

Appendix 3. Evolution of the research question………………………………………………283

Appendix 4. Data access agreement……………………………………………………………286

Appendix 5. Deed of novation……………………………………………………………………292

Appendix 6. Pharmacist focus group pre-reading material ……………………………298

Appendix 7. Data analysis of pharmacist focus group interviews …………………………301

Appendix 8. Establishment of patient typologies……………………………………………306

Appendix 9. Analysis of patients’ views on privacy……………………………………………332

Appendix 10. Analysis of patients’ views on privacy by typology…………………………335

References ………………………………………………………………………………………338
List of Tables

Table 1 Schedules of medicines in Australia .......................................................... 33
Table 2 Number of OST patients per program in SA in June 2013 ......................... 37
Table 3 Number of OST patients per provider in SA in April 2011 ......................... 40
Table 4 International prescribing models ................................................................ 47
Table 5 Pharmacist prescriber roles abroad and the patient/system benefits reported .. 49
Table 6 The equivalent of methadone (controlled drug in Australia) prescribing in the UK and USA ........................................................................................................... 50
Table 7 Patient interview schedule ........................................................................ 79
Table 8 Interviewed patient demographics ............................................................. 81
Table 9 The five steps of analysis using the framework approach ............................. 83
Table 10 Participants who attended and the rural classification of their pharmacy .... 88
Table 11 Pharmacist focus group interview outline ............................................... 89
Table 12 Focus group participant demographic details .......................................... 90
Table 13 What are patients’ experiences with the existing model? ......................... 104
Table 14 Quotations from difficult and easy access patients about initial treatment access .................................................................................................................. 107
Table 15 From the perspective of patients, how could pharmacist co-prescribing impact on the delivery of opioid substitution treatment? ................................................................. 136
Table 16 Comparison of themes between Chapter 5 and Chapter 6 ....................... 137
Table 17 Comparison of patient views about pharmacist relationship and their views on pharmacy privacy ............................................................................................................ 163
Table 18 Main themes and sub-themes from pharmacist focus group interviews ...... 168
Table 19 Comparative demographics of California, Alberta and South Australia .... 225
Table 20 Physician and pharmacist density in USA, Canada and Australia ............ 225
Table 21 Study tour key insights ............................................................................ 227
Table 22 Discussion themes which recur across findings in Chapters 5 to 9 ............ 242
Table 23 Anticipated codes from patient interviews 10 March 2011 ....................... 275
Table 24 Thematic index from patient interviews on 24 May 2011 ........................ 276
Table 25 Monitoring of codes after each interview for data saturation .................. 279
Table 26 Thematic charts created from patient interview transcripts on 13 Sep 2011..... 280
Table 27 Anticipated codes prior to focus group interviews 15 May 2012 .................. 301
Table 28 Thematic index from focus group transcripts on 23 May 2012 .................. 302
Table 29 Thematic index from focus group transcripts on 31 May 2012 .................. 303
Table 30 Thematic charts from focus group transcripts on 4 June 2012 .................. 304
Table 31 Quotations from easy access and difficult access typology patients about initial treatment access ........................................................................................................... 306
Table 32 Easy access and difficult access typology patient perceptions .................. 307
Table 33 Establishment of patient typologies ............................................................ 308
Table 34 Analysis of the main themes according to the easy access and difficult access patient typologies ........................................................................................................ 318
Table 35 Patients’ views on pharmacy privacy by dosing area ................................ 332
Table 36 Patients’ views on privacy by typology ...................................................... 335

List of Figures

Figure 1 Model of entry and exit points for patients through the treatment process in South Australia .................................................................................................................... 35
Figure 2 Number of patients receiving opioid pharmacotherapy treatment for drug dependence in South Australia ........................................................................................................ 38
Figure 3 Pharmacist response rate to the focus group interviews .......................... 87
Figure 4 Types of pharmacist prescribing in Alberta ............................................. 231
Figure 5 Model for continuing quality improvement for prescribing education .... 252
Figure 6 Data saturation monitor ........................................................................... 279
# Glossary

<p>| Term                                                                 | Definition                                                                                                                                                                                                 |
|                                                                     | A community pharmacy deals directly with consumers in their local area. It has responsibilities including the checking, dispensing and supply of medicines in accordance with the prescription or, when legally permitted, the sale of medicines without a prescription. Other professional activities include patient counselling and compounding of medications. There is a legal requirement for a registered pharmacist to be on site. |
|                                                                     | Any member of the public who uses, has used or is a potential user of a health service.                                                                                                                                                                     |
| Dependent prescriber                                                | Dependent prescribers do not establish the patient’s diagnosis, but they carry out ongoing patient care roles. Under this arrangement, the doctor (independent prescriber) diagnoses; then the dependent prescriber monitors and continues the patient’s treatment.                                   |
| Detoxification/withdrawal program                                   | A process which involves the transfer of patients from an opioid to a drug-free state through the provision of reduced doses of buprenorphine/naloxone over a period of days.                                                                                     |
| Drug and Alcohol Services South Australia (DASSA)                  | Drug and Alcohol Services South Australia (DASSA) is a statewide health service and is responsible to the Minister for Mental Health and Substance Abuse. It is governed by the South Australian Department for Health and Ageing and addresses alcohol, tobacco, and pharmaceutical and illicit drug issues across the state. The DASSA pharmacy is a specialist clinic pharmacy and is not defined as either a community or hospital pharmacy. |
| Drugs of Dependence Unit (DDU)                                     | The Drugs of Dependence Unit (DDU) is a regulatory body responsible for administering those parts of the Controlled Substances Act 1984 relating to drugs of dependence.                                                                                       |
| Independent prescriber                                             | Independent prescribers have sole responsibility for the patient’s assessment, diagnosis and clinical management.                                                                                                                                               |
| Medicare                                                            | Medicare is Australia’s universal public health system. Australian citizens and permanent residents have access to free treatment in public hospitals. They can also receive subsidised treatment from medical practitioners, eligible midwives, nurse practitioners and allied health professionals who have an allocated Medicare provider number. |</p>
<table>
<thead>
<tr>
<th>Non-medical practitioner/prescriber</th>
<th>Prescribing of medication by specially trained health professionals, other than doctors and dentists, working within their clinical competence as either independent and/or dependent prescribers.</th>
</tr>
</thead>
<tbody>
<tr>
<td>OST</td>
<td>Opioid substitution treatment. Refers to methadone, buprenorphine or buprenorphine/naloxone treatment for opioid-dependent patients.</td>
</tr>
<tr>
<td>Patient</td>
<td>Registered user of the health care service provider.</td>
</tr>
<tr>
<td>Pharmaceutical Benefits Scheme (PBS)</td>
<td>The Pharmaceutical Benefits Scheme (PBS) provides Australian citizens and permanent residents with access to affordable and timely prescription medications. The PBS subsidises the cost of listed prescription medicines, making access to medications more affordable for all Australians.</td>
</tr>
<tr>
<td>Scope of practice</td>
<td>The area and extent of practice for a health professional with consideration of their education, experience, expertise and demonstrated competency.</td>
</tr>
<tr>
<td>Take-away dose</td>
<td>A dose that is consumed by an opioid substitution treatment (OST) patient without supervision by a health professional. Take-away doses require specific preparation to ensure that the dose is administered correctly and safely without supervision.</td>
</tr>
</tbody>
</table>
Abstract

In Australia, the demand for prescribers to service opioid substitution treatment (OST) patients exceeds the interest of general practitioners in fulfilling this prescribing role. One response to meet unmet prescribing demands which has been introduced internationally is the use of pharmacist prescribing for a range of chronic medical conditions, including for OST.

In this thesis, I explore a policy proposal for pharmacists to prescribe OST collaboratively (co-prescribing) with doctors. To examine this policy and its implications, I collected data from three sources: face-to-face interviews with 14 OST patients, three focus group interviews with 18 South Australian pharmacists and a study tour of pharmacist prescribing in Alberta, Canada and California, USA. A total of 28 key informants were met with during the study tour. This included people based in a range of research/academic units (5), policy/governance bodies (3), clinical sites where pharmacist prescribing was practised (12) and sites which provided an understanding of the health care system (8).

My key findings are as follows.

First, OST patients had varied experiences with the existing model of care. They reported varying levels of treatment access, varied degrees of pharmacist supervision and a lack of continuity of care from clinic doctors. They also displayed a range of attitudes toward the need for privacy. Although most patients valued privacy to some degree, not all did: indeed, the same layout was experienced and perceived differently by different patients.

Second, the current model of OST care draws on a prescription approach to pharmacy practice, whereas co-prescribing is more aligned with patient-centred care. Under the current model of care, pharmacists are limited in their ability to actively respond to OST patient needs because their activities are primarily focused on the prescription directions. In contrast, pharmacist co-prescribing can deliver aspects of patient-centred care that cannot be provided as effectively through conventional care. It offers flexibility for the pharmacist to respond to the patient’s needs. This includes enhanced patient participation in treatment decisions, access to treatment and respect/privacy. Co-prescribing also offers
continuity of treatment care due to the therapeutic relationship which already exists between a pharmacist and a patient from supervised dosing.

Third, the experience of Albertan and Californian pharmacist prescribers suggests that it should be possible for Australian pharmacists to pursue similar responsibilities. These roles are possible in both hospital and community pharmacy settings, provided key facilitators are addressed.

My research acknowledges that there are various challenges for pharmacist prescribing. However, the perspectives of the patients and pharmacists in my study, in conjunction with insights from Alberta and California, can be used to formulate a strategy for collaborative prescribing for OST patients in South Australia.
Acknowledgements

I could have only completed this doctoral thesis over the last four years with the support of many people. I would like to extend my gratitude and thanks especially to the following people.

I must acknowledge the support of my supervisory team. Foremost, I sincerely thank my primary supervisor Professor Annette Braunack-Mayer. I have learnt an enormous amount about qualitative research and writing from her. Under her guidance, I have been able to achieve a level of depth in data examination that I thought was beyond my ability. She has also converted me into an active tense writer! I appreciate all of her contributions and comments which have been crucial to me finalising my thesis. I am also thankful for the excellent example that she has been as a successful academic, leader and mentor. Without her supervision, completion of my thesis definitely would not have been possible. In addition, thank you to my co-supervisor Associate Professor Caroline Laurence (who entered my panel at a later date) for her feedback comments.

I also acknowledge Drug and Alcohol Services Australia and the Drugs of Dependence Unit, SA Health for their data and access contributions to my research. Thank you to Simone Cormack and Dr Chris Holmwood for your support of my research. Special thanks also to Kathy Larrigy and June Chin for your library assistance throughout my research. Many thanks are also due to Geoff Anderson for taking the time to provide me with support and feedback at various stages. Note that any opinions expressed in this thesis are not necessarily a reflection of SA Health’s views.

Thank you to the Freemasons Memorial Scholarship which funded my study tour. It was this study tour which changed me and my vision for my research. Particular thanks are also due to the individuals who contributed to my study tour as well as to the participants who contributed to make my research possible.

I wish to acknowledge Valerie Williams for her professional editing as well as Dr Jean-Pierre Calabretto for his feedback comments on the sections about Australian health informatics.
Some data were also obtained which did not make it into my thesis, but this does not discount the time and enormous effort that many people contributed to this process. Many thanks to David Watts and Susan O’Neill for your assistance with data access agreement negotiations. Thank you also to Sonia Podreka and Graeme Smith for data management assistance as well as Chris Medelin for assistance with the mapping software.

Special thanks to friends and colleagues who have encouraged me during my PhD journey. Particular thanks to my fellow postgraduate colleagues, David Andrew Johnson, Dr Vicki Xafis and Thomas Vreugdenburg who have shared this journey with me. They have provided me with friendship and feedback that have made this experience more valuable. Thank you also to Anne Madigan who supported me when I felt powerless.

I would like to extend deepest thanks to my family for their support before and during my PhD journey. Thank you to my parents who taught me the importance of education and for giving me a strong foundation on which to build my life. When I wanted to give up, I remembered that they never had the option of giving up, so neither should I. Thank you also to my parents-in-law, sister, brother-in-law and brother for their understanding throughout the duration of my research. In addition, thank you to my niece and nephew whose bright smiles always made me feel better.

Four months after my thesis submission, my son was born. His expected arrival was a strong motivation for me to complete my thesis in a timely manner. Now having him in my life fulfils me more than any other achievement, including that of this doctoral completion.

My wholehearted thanks go to my husband who has lived this PhD experience with me. It is because of your support that I have been able to pursue, continue and complete this thesis. Thank you for driving me to uni and picking me up almost every time I had to go to the office – even on the weekends. Our lives have changes so much since I started this PhD. We got engaged, married and had a son during this four year period. But the one thing that has not changed is that everything means nothing unless we are travelling together.